Category Archives: Drug pricing

Myth busters take on drug prices, or do they?

Hoping to debunk biopharma’s biggest justification for high drug prices, Public Citizen released a report Monday showing that the 20 biggest drug companies collectively generated more than $100 billion in annual profits from 2013 through 2015, nearly double what a…

Share

Is ‘what the patient pays’ the right barometer for pricing drugs?

Just a few months ago, Mylan NV got caught in a net of its own making when it raised the U.S. list price for a two-pack of its Epipen to $608, a 550 percent increase over several years. The hue…

Share

Yes, there’s a doctor in the House (and Senate)

It was out with the old and in with the new Tuesday as the 114th U.S. Congress gave way to the 115th. Among the new delegates taking their seats in the House were a few more doctors, a dentist and…

Share

Rules of the PAP road not always clear, even to seasoned travelers

As a veteran health care journalist, I appreciate the need for biopharmas to recoup R&D costs and to operate profitably, so it’s hardly surprising to me when newly approved drugs are priced at a premium. But I’m also a consumer…

Share

An end to Charlotte’s web?

In the annals of popular literature, TV shows and movie scripts, only a handful of pigs have achieved mega stardom: Napoleon, who took over a farm and assassinated his political rivals; Arnold, who epitomized the couch potato at Green Acres;…

Share

Shkreli: A supervillain with a dastardly plan? Or a distraction from the real problem?

As the saga of Martin Shkreli continues to unfold in all its obnoxious glory, with every tweet and smirk signifying the former biopharma CEO’s apparent aspirations to a level of sheer jerkiness heretofore unseen on planet Earth, there’s one question…

Share

Better Rx needed to treat drugmakers’ PR malady

Biopharma has a bad PR disease. The diagnosis is pretium offensus, otherwise known as “sticker shock.” The infectious condition has two causes: enormous, inexplicable, overnight price hikes and six-figure drug prices that spread from headlines to become a viral meme…

Share

The next episode of the American horror story

You’ve likely heard the terrified screams induced by the cost of pricey cancer drugs, Gilead Sciences Inc.’s twin hepatitis C therapies and Vertex’s cystic fibrosis breakthroughs. And you may have been rattled by the nightmarish predictions about how a new…

Share

You’ve come a long way, baby, but still a long way to go

Patients have come a long way to get a say in the drug development and approval process. But there’s still some ground to cover if they’re going to move from the passive subject role to a 50-50 partnership that reminds…

Share

Old news, yet still making headlines

High drug prices are old news. Old, as in 19th century old. But that doesn’t mean they aren’t breaking news today. Breaking, as in breaking the family budget. One of the speakers at the Institute of Medicines National Cancer Policy…

Share